Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
177.35 USD   -3.98%
12/09Insider Sell: Moderna
MT
12/09Insider Sell: Moderna
MT
12/09U.S. CDC expands use of bivalent COVID vaccines for kids as young as 6 months
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna refused China request to reveal vaccine technology - FT

10/01/2022 | 08:05pm EST
A sign marks the headquarters of Moderna in Cambridge

(Reuters) - Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.

The Cambridge, Massachusetts-based pharmaceutical company turned down China's request to hand over the recipe for its mRNA vaccine because of commercial and safety concerns, the newspaper said, citing people involved in negotiations that took place between 2020 and 2021, adding that the vaccine maker is still "eager" to sell the product to China.

The company had "given up" on its previous efforts to access the Chinese market because of China's demand that it hand over the technology as a prerequisite for selling in the country, the report said.

Moderna did not immediately respond to Reuters' request for comment.

China has not approved any foreign COVID-19 vaccines and relies on several domestically developed shots.

In September, Moderna Chief Medical Officer Paul Burton had said the company was keen to collaborate with China on supplying its mRNA-based COVID-19 vaccines to the country.

"We would certainly be very eager to collaborate with China if they felt that there was a need for a vaccine there," Burton had told a media briefing for reporters in Asia. "Currently, there is no activity going on, but we'd be very open to it."

(Reporting by Rhea Binoy in Bengaluru; editing by Jonathan Oatis)


ę Reuters 2022
All news about MODERNA, INC.
12/09Insider Sell: Moderna
MT
12/09Insider Sell: Moderna
MT
12/09U.S. CDC expands use of bivalent COVID vaccines for kids as young as 6 months
RE
12/09US CDC Expands Bivalent COVID-19 Vaccines to Children
MT
12/09White House doctors urge Americans to get updated COVID boosters
RE
12/09Coronavirus Update FDA Authorizes Updated COVID-19 Vaccines for Children Down to 6 Mont..
AQ
12/09Parainfluenza Virus Infection Pipeline as Novel and Extensive 5+ Therapies Likely to En..
AQ
12/08S&P snaps losing streak on jobless claims rise
RE
12/08S&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
12/08S&P 500 snaps losing streak on jobless claims rise
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 089 M - -
Net income 2022 8 897 M - -
Net cash 2022 12 022 M - -
P/E ratio 2022 8,22x
Yield 2022 -
Capitalization 68 134 M 68 134 M -
EV / Sales 2022 2,94x
EV / Sales 2023 6,20x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 177,35 $
Average target price 211,25 $
Spread / Average Target 19,1%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-27.28%68 134
IQVIA HOLDINGS INC.-25.42%39 082
LONZA GROUP AG-39.99%36 246
ALNYLAM PHARMACEUTICALS, INC.40.35%29 282
SEAGEN INC.-19.79%23 253
CELLTRION, INC.-8.84%18 466